Figure 2 delineates the principal therapeutic intervention sites, with PSMA as the central molecular entity. This molecule exhibits low expression on normal cells, high expression on cancer cells, and is localized on the cell surface. Consequently, it represents an ideal candidate for direct radiolabeling or targeting through specific pharmaceutical inhibitors [28]. PSMA has been implicated in therapy resistance and in the progression of PC to an untreatable stage [22]. The gene discussed is FOLH1; the disease is pachyonychia congenita.